Skip to content

ORAL AZITHROMYCIN VS DOXYCYCLINE IN TREATMENT OF CHILDREN WITH SCRUB TYPHUS WITHOUT COMPLICATIONS

ORAL AZITHROMYCIN VS DOXYCYCLINE IN TREATMENT OF CHILDREN WITH SCRUB TYPHUS WITHOUT COMPLICATIONS - AN OPEN LABEL RANDOMIZED CONTROLLED TRIAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/01/017012
Enrollment
124
Registered
2019-01-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A753- Typhus fever due to Rickettsia tsutsugamushi

Interventions

Intervention1: Azithromycin: 10mg/Kg/Day once daily for 5 days Control Intervention1: Doxycycline: 4.5mg/kg/day divided Q 12 Hourly for 5 days

Sponsors

Dr Joseph John
Lead Sponsor
Dr Amit Kumar Satapathy
Collaborator
Dr Bijayani Behera
Collaborator
Dr Biswa Mohan Padhy
Collaborator
Dr Karthika I K
Collaborator
Dr Suchanda Sahu
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Patients falling under the â??suspected, probable and confirmed case definitions â?? as per IAP guidelines on Ricketssial diseases in children based on clinical and epidemiological criterias

Exclusion criteria

Exclusion criteria: Patients with a known allergy to either of these drugs Patients participating in other clinical trials Children with any other known systemic illness Children with any major congenital malformations   Children who have received antimicrobial drugs with antirickettsial activity in the preceeding 2 weeks (doxycycline/azithromycin/chloramphenicol/rifampicin)

Design outcomes

Primary

MeasureTime frame
To compare the efficacy of two drugs in terms of percentage of children who attained remission of fever after 72 hours of administration of first dose of the study drugTimepoint: After 72 hours of administration of first dose of the study drug

Secondary

MeasureTime frame
Adverse drug events of the medications being usedTimepoint: On a daily basis;Clinical resolution of hepatosplenomegaly and lymphadenopathy. Timepoint: On a daily basis;Rate of treatment failuresTimepoint: After 72 hours;Time required for normalization of a)Liver enzymes - AST and ALT between 40 U/L b)Thrombocytopenia - Platelet count 1.5 lakhs c)Hyponatremia - Serum Sodium 135 mEq/L d)Hypoalbuminemia- Albumin 3.5g/dLTimepoint: On Day 3 and Day 5 and in selected cases who have not responded to repeat after 1 week of administration of the study drug;Time taken for defervescence of fever for either drug after the first dose of drugTimepoint: Monitored every 4 hourly

Countries

India

Contacts

Public ContactDr Karthika I K

All India Institute of Medical Sciences, Bhubaneswar

drjj@rediffmail.com7559936936

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026